DE602007003543D1 - EML4-ALK-Fusionsgen - Google Patents
EML4-ALK-FusionsgenInfo
- Publication number
- DE602007003543D1 DE602007003543D1 DE200760003543 DE602007003543T DE602007003543D1 DE 602007003543 D1 DE602007003543 D1 DE 602007003543D1 DE 200760003543 DE200760003543 DE 200760003543 DE 602007003543 T DE602007003543 T DE 602007003543T DE 602007003543 D1 DE602007003543 D1 DE 602007003543D1
- Authority
- DE
- Germany
- Prior art keywords
- fusion gene
- cancer
- present
- eml4
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004927 fusion Effects 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 108700020796 Oncogene Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006277718 | 2006-10-11 | ||
| JP2007120670 | 2007-05-01 | ||
| CA 2598893 CA2598893C (en) | 2006-10-11 | 2007-08-24 | Eml4-alk fusion gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602007003543D1 true DE602007003543D1 (de) | 2010-01-14 |
Family
ID=39277176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE200760003543 Active DE602007003543D1 (de) | 2006-10-11 | 2007-10-11 | EML4-ALK-Fusionsgen |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US7728120B2 (https=) |
| EP (1) | EP2116553B1 (https=) |
| JP (2) | JP4303303B2 (https=) |
| AT (1) | ATE450547T1 (https=) |
| CA (1) | CA2598893C (https=) |
| DE (1) | DE602007003543D1 (https=) |
| ES (2) | ES2335368T3 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| PT2450437T (pt) * | 2006-04-14 | 2017-08-25 | Cell Signaling Technology Inc | Defeitos de genes e cinase alk mutante em tumores sólidos humanos |
| ES2458497T3 (es) * | 2006-04-14 | 2014-05-05 | Cell Signaling Technology, Inc. | Defectos de genes y quinasa ALK mutante en tumores sólidos humanos |
| US8168383B2 (en) * | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| EP2255190A4 (en) * | 2008-02-12 | 2011-05-04 | Brigham & Womens Hospital | FISH TEST FOR EML4-ALK FUSION IN LUNG CANCER |
| JP2009219728A (ja) * | 2008-03-18 | 2009-10-01 | Daito Giken:Kk | 遊技台 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| MX353308B (es) | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| AU2010248782B2 (en) * | 2009-05-15 | 2015-06-11 | Insight Genetics, Inc. | Methods and compositions relating to fusions of ALK for diagnosing and treating cancer |
| WO2011043220A1 (ja) | 2009-10-06 | 2011-04-14 | 富士レビオ株式会社 | 融合遺伝子の測定方法 |
| US9175350B2 (en) | 2009-12-22 | 2015-11-03 | Quest Diagnostics Investments Incorporated | EML4-ALK translocations in lung cancer |
| WO2011102507A1 (ja) * | 2010-02-22 | 2011-08-25 | 富士レビオ株式会社 | 癌遺伝子の同定方法、癌遺伝子発現細胞の樹立方法、および癌遺伝子標的薬のスクリーニング方法 |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| WO2011130635A2 (en) * | 2010-04-16 | 2011-10-20 | Response Genetics, Inc. | Primers, probes, methods and kits for the detection of eml4-alk variants |
| US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
| CN103052386B (zh) | 2010-08-20 | 2016-03-02 | 中外制药株式会社 | 含有四环化合物的组合物 |
| EP2620497B1 (en) * | 2010-09-02 | 2017-10-11 | Kurume University | Method for producing circular dna formed from single-molecule dna |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| JP5769952B2 (ja) * | 2010-11-12 | 2015-08-26 | 株式会社Ｌｓｉメディエンス | Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法 |
| WO2012075318A2 (en) * | 2010-12-01 | 2012-06-07 | Cell Signaling Technology, Inc. | Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer |
| RS54189B1 (sr) * | 2011-02-02 | 2015-12-31 | Novartis Ag | Postupci za korišćenje inibitora alk |
| WO2012139134A2 (en) * | 2011-04-07 | 2012-10-11 | Coferon, Inc. | Methods of modulating oncogenic fusion proteins |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| JP6066209B2 (ja) * | 2011-08-31 | 2017-01-25 | 学校法人 久留米大学 | Ｄｎａ分子の環状化において単分子による環状化ｄｎａのみを選別する方法 |
| PL2838998T3 (pl) | 2012-04-18 | 2018-04-30 | Cell Signaling Technology, Inc. | EGFR i ROS1 w nowotworze |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US9084456B1 (en) * | 2012-05-28 | 2015-07-21 | Jack Zemer | Linkage for jewelry components |
| US9597348B2 (en) | 2012-09-06 | 2017-03-21 | Epizyme, Inc. | Method of treating leukemia |
| CA2894220A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Dot1l inhibitors for use in the treatment of leukemia |
| JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| US10705087B2 (en) | 2013-07-26 | 2020-07-07 | Japanese Foundation For Cancer Research | Detection method for NTRK3 fusion |
| WO2015064620A1 (ja) * | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| JPWO2015064621A1 (ja) * | 2013-10-29 | 2017-03-09 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| WO2015111716A1 (ja) | 2014-01-24 | 2015-07-30 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| TWI831128B (zh) | 2014-04-25 | 2024-02-01 | 日商中外製藥股份有限公司 | 以高用量含有４環性化合物的製劑 |
| JP6873698B2 (ja) | 2014-04-25 | 2021-05-19 | 中外製薬株式会社 | ４環性化合物の新規結晶 |
| TWI803187B (zh) | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
| EP2990493B1 (en) | 2014-09-01 | 2017-05-24 | ARKRAY, Inc. | Primer reagent for amplifying alk fusion gene, alk fusion gene amplification reagent kit including the same, and alk fusion gene amplification method and alk fusion gene analysis method using the same |
| JP7015171B2 (ja) | 2016-01-15 | 2022-02-02 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| JP6740172B2 (ja) * | 2017-05-02 | 2020-08-12 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ |
| WO2020006314A1 (en) * | 2018-06-27 | 2020-01-02 | City Of Hope | Modification of small rnas for therapeutic uses |
| BR112020025499A2 (pt) | 2018-06-29 | 2021-03-09 | Chugai Seiyaku Kabushiki Kaisha | Composição farmacêutica que compreende agente básico pouco solúvel |
| JP7385191B2 (ja) * | 2019-08-30 | 2023-11-22 | 学校法人同志社 | Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬 |
| JP2020156481A (ja) * | 2020-04-06 | 2020-10-01 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ |
| JP7849382B2 (ja) | 2021-10-28 | 2026-04-21 | 中外製薬株式会社 | シロップ剤 |
| AU2023304031A1 (en) | 2022-07-04 | 2025-02-06 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
| TW202425998A (zh) | 2022-08-30 | 2024-07-01 | 日商中外製藥股份有限公司 | 併用醫藥 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716613B1 (en) | 1999-11-11 | 2004-04-06 | Yamanouchi Pharmaceutical Co., Ltd. | Metalloprotease having aggrecanase activity |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
| PT1660458E (pt) | 2003-08-15 | 2012-04-27 | Novartis Ag | 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário |
| JP2008502595A (ja) | 2004-03-31 | 2008-01-31 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼモジュレータおよびその使用方法 |
| ES2458497T3 (es) | 2006-04-14 | 2014-05-05 | Cell Signaling Technology, Inc. | Defectos de genes y quinasa ALK mutante en tumores sólidos humanos |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
-
2007
- 2007-08-24 CA CA 2598893 patent/CA2598893C/en active Active
- 2007-08-27 US US11/845,498 patent/US7728120B2/en active Active
- 2007-10-11 ES ES07254044T patent/ES2335368T3/es active Active
- 2007-10-11 DE DE200760003543 patent/DE602007003543D1/de active Active
- 2007-10-11 AT AT07254044T patent/ATE450547T1/de not_active IP Right Cessation
- 2007-10-11 EP EP20090006058 patent/EP2116553B1/en active Active
- 2007-10-11 JP JP2007265917A patent/JP4303303B2/ja active Active
- 2007-10-11 ES ES09006058.3T patent/ES2515170T3/es active Active
-
2008
- 2008-04-10 US US12/100,595 patent/US7605131B2/en active Active
-
2009
- 2009-02-18 JP JP2009035918A patent/JP5172736B2/ja active Active
- 2009-05-15 US US12/466,920 patent/US7964710B2/en active Active
-
2011
- 2011-04-13 US US13/086,245 patent/US8197818B2/en active Active
-
2012
- 2012-05-10 US US13/468,730 patent/US9029521B2/en active Active
-
2015
- 2015-03-10 US US14/643,181 patent/US9932589B2/en active Active
-
2017
- 2017-11-13 US US15/810,918 patent/US20180066266A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150184161A1 (en) | 2015-07-02 |
| US20100240673A1 (en) | 2010-09-23 |
| US9029521B2 (en) | 2015-05-12 |
| EP2116553A1 (en) | 2009-11-11 |
| US9932589B2 (en) | 2018-04-03 |
| US7964710B2 (en) | 2011-06-21 |
| JP5172736B2 (ja) | 2013-03-27 |
| CA2598893A1 (en) | 2008-04-11 |
| EP2116553B1 (en) | 2014-07-30 |
| JP2008295444A (ja) | 2008-12-11 |
| US7728120B2 (en) | 2010-06-01 |
| CA2598893C (en) | 2012-04-10 |
| US20090099193A1 (en) | 2009-04-16 |
| JP2009100783A (ja) | 2009-05-14 |
| US20130158095A1 (en) | 2013-06-20 |
| US8197818B2 (en) | 2012-06-12 |
| ES2515170T3 (es) | 2014-10-29 |
| ES2335368T3 (es) | 2010-03-25 |
| ATE450547T1 (de) | 2009-12-15 |
| US7605131B2 (en) | 2009-10-20 |
| US20110230545A1 (en) | 2011-09-22 |
| JP4303303B2 (ja) | 2009-07-29 |
| US20180066266A1 (en) | 2018-03-08 |
| US20080090776A1 (en) | 2008-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE450547T1 (de) | Eml4-alk-fusionsgen | |
| EA200702203A1 (ru) | Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений | |
| DE602005009702D1 (de) | Esr1 und gebärmutterhalskrebs | |
| TW200745556A (en) | Biomarkers for liver fibrotic injury | |
| WO2011119934A3 (en) | Methods and materials for detecting colorectal neoplasm | |
| WO2013033629A3 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
| MX2012001716A (es) | Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf. | |
| WO2008089994A8 (en) | Use of igfbp-7 in the assessment of heart failure | |
| WO2009019368A3 (fr) | Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal | |
| ATE511645T1 (de) | Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme | |
| ATE533838T1 (de) | Verfahren zur verbesserten einführung von dna in bakterienzellen | |
| WO2008012362A3 (en) | New protein isoforms and uses thereof | |
| WO2008073177A3 (en) | Expression profiles associated with irinotecan treatment | |
| WO2007103146A3 (en) | Truncated proteins as cancer markers | |
| WO2007100859A3 (en) | Gene predictors of response to metastatic colorectal chemotherapy | |
| IL179441A0 (en) | Hif prolyl hydroxylase activity assay | |
| TW200626899A (en) | Frizzled proteins and detection and treatment of cancer | |
| TW200626900A (en) | Wnt proteins and detection and treatment of cancer | |
| WO2012064035A3 (ko) | Ｐｎａ 기반의 실시간 ｐｃｒ 클램핑을 이용한 ｂｃｒ-ａｂｌ 융합 유전자의 돌연변이 검출 방법 및 키트 | |
| MX2009004382A (es) | Variaciones geneticas asociadas con tumores. | |
| WO2004074441A3 (en) | Amplification or overexpression of mll septin-like fusion (msf) and septin9 and methods related thereto | |
| ATE462803T1 (de) | Kit und verfahren zum nachweis von urothelkarzinom | |
| MX2011006773A (es) | Biomarcador. | |
| DK1694697T3 (da) | Overfladelokaliserede Campylobacter jejuni-polypeptider | |
| WO2009126804A3 (en) | Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |